Medroxyprogesterone Acetate News and Research

RSS

Apigenin effective against human breast cancer

Apigenin, a natural substance found in grocery store produce aisles, shows promise as a non-toxic treatment for an aggressive form of human breast cancer, following a new study at the University of Missouri.

17 May 2012

Breast cancer screening false positive results may need more follow up: Study

A Danish study of more than 58,000 women found those who had false positive mammograms, meaning the results suggested breast cancer when there was none, had a 67 percent higher risk of developing breast cancer later in life compared with women who had negative mammograms.

5 Apr 2012

Injectable form of progestin may increase breast cancer risk in young women

The first large-scale U.S.-based study to evaluate the link between an injectable form of progestin-only birth control and breast cancer risk in young women has found that recent use of a year or more doubles the risk.

5 Apr 2012

Significant number of young women fail to recognize recent weight gain

Despite popular belief about women's weight concerns, young women commonly fail to recognize recent gain of as many as 11 pounds - putting them at risk for cardiovascular disease and other obesity-related conditions.

11 Jan 2012

Birth control shot may impair a person's memory

The birth control shot Depo Provera offers a convenient alternative for women who don't want to remember to take a daily pill. Ironically, research from Arizona State University has shown the shot actually may impair a person's memory.

2 Nov 2011

$DMPA injectible contraceptive associated with increased risk of bone fracture$

DMPA injectible contraceptive associated with increased risk of bone fracture

A new study presented today at the World Congress on Osteoporosis (IOF WCO-ECCEO10) in Florence, Italy shows that DMPA, a commonly used injectible contraceptive, is associated with higher risk of bone fracture when used alone, and not in combination with estrogens.

7 May 2010

Postmenopausal women undergoing combination hormone therapy at increased risk of heart disease: WHI confirms

New analyses from the Women's Health Initiative (WHI) confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women. Researchers report a trend toward an increased risk of heart disease during the first two years of hormone therapy among women who began therapy within 10 years of menopause, and a more marked elevation of risk among women who began hormone therapy more than 10 years after menopause. Analyses indicate that overall a woman's risk of heart disease more than doubles within the first two years of taking combination HT.

17 Feb 2010

Women using DMPA experience high BMD loss, researchers say

Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two years of beginning the contraceptive, according to researchers at the University of Texas Medical Branch at Galveston.

22 Dec 2009

Hormone therapy: An important treatment option for post-menopausal women

In connection with the New York Times’ recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper’s account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines.

14 Dec 2009

Breast tenderness indicates increased cancer risk among women on combination therapy

Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study.

13 Oct 2009

Researchers identify women at risk of gaining excessive weight with Depo-Provera

Researchers at the University of Texas Medical Branch at Galveston have identified women who are likely to gain weight while using depot medroxyprogesterone acetate, more commonly known as Depo-Provera or the birth control shot. These findings dispel the myth that all women who use DMPA will gain weight and will help physicians to counsel patients appropriately.

24 Jul 2009

Birth control shot causes significant weight gain

Women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, gained an average of 11 pounds and increased their body fat by 3.4 percent over three years, according to researchers at the University of Texas Medical Branch (UTMB).

4 Mar 2009

New cream for vaginal dryness approved

Barr Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its subsidiary Duramed Pharmaceuticals, Inc.'s New Drug Application (NDA) for Synthetic Conjugated Estrogens-A (SCE-A) 0.625 mg/g Vaginal Cream.

1 Dec 2008

Synthetic progestin linked to breast cancer

Millions of post-menopausal women use hormone replacement therapy (HRT) as a method to reduce symptoms associated with menopause.

2 Apr 2008

Long-term effects of synthetic progestins cause for concern

The widely used synthetic progestin medroxyprogesterone acetate (MPA) decreased endothelial function in premenopausal women in a study done at the University of Oregon.

11 Mar 2008

Risks of long-term hormone therapy continue to outweigh benefits

New results from the Women's Health Initiative (WHI) confirm that the health risks of long-term use of combination (estrogen plus progestin) hormone therapy in healthy, postmenopausal women persist even a few years after stopping the drugs and clearly outweigh the benefits.

6 Mar 2008

Hormone therapy increases frequency of abnormal mammograms, breast biopsies

Combined hormone therapy appears to increase the risk that women will have abnormal mammograms and breast biopsies, and it may decrease the effectiveness of both methods for detecting breast cancer, according to a report in the Feb. 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Feb 2008

Wyeth wins HRT trial

Wyeth has announced that the jury in the case of Merle and Steven Simon v. Wyeth, in the Philadelphia Court of Common Pleas, found in favor of Wyeth.

16 May 2007

International Menopause Society reaction to report on breast cancer

A special report in the April 19 issue of the New England Journal of Medicine [1] brings initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology and End Result (SEER) registries, showing that the incidence of breast cancer in women in the US fell by 6.7% in 2003, and stayed at the same level in 2004.

20 Apr 2007

No apparent increase in coronary heart disease for women who initiate hormone therapy

Wyeth Pharmaceuticals, a division of Wyeth ( NYSE:WYE ) , provides comment on a re- analysis of pooled data from both hormone therapy arms of the Women's Health Initiative (WHI) Study published today in the Journal of the American Medical Association.

4 Apr 2007